{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:24:50Z","timestamp":1777515890036,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\u2013NIA","award":["R01AG057896, 1RF1AG063507, R01AG068293, 1R01AG0665241A,1R01AG065301, P30 AG066546"],"award-info":[{"award-number":["R01AG057896, 1RF1AG063507, R01AG068293, 1R01AG0665241A,1R01AG065301, P30 AG066546"]}]},{"name":"NIH\u2013NINDS","award":["RF1NS112391, U19NS115388"],"award-info":[{"award-number":["RF1NS112391, U19NS115388"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Selective drugs with a relatively narrow spectrum can reduce the side effects of treatments compared to broad-spectrum antibiotics by specifically targeting the pathogens responsible for infection. Furthermore, combating an infectious pathogen, especially a drug-resistant microorganism, is more efficient by attacking multiple targets. Here, we combined synthetic lethality with selective drug targeting to identify multi-target and organism-specific potential drug candidates by systematically analyzing the genome-scale metabolic models of six different microorganisms. By considering microorganisms as targeted or conserved in groups ranging from one to six members, we designed 665 individual case studies. For each case, we identified single essential reactions as well as double, triple, and quadruple synthetic lethal reaction sets that are lethal for targeted microorganisms and neutral for conserved ones. As expected, the number of obtained solutions for each case depends on the genomic similarity between the studied microorganisms. Mapping the identified potential drug targets to their corresponding pathways highlighted the importance of key subsystems such as cell envelope biosynthesis, glycerophospholipid metabolism, membrane lipid metabolism, and the nucleotide salvage pathway. To assist in the validation and further investigation of our proposed potential drug targets, we introduced two sets of targets that can theoretically address a substantial portion of the 665 cases. We expect that the obtained solutions provide valuable insights into designing narrow-spectrum drugs that selectively cause system-wide damage only to the target microorganisms.<\/jats:p>","DOI":"10.1038\/s41598-024-65936-y","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T13:02:14Z","timestamp":1721134934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systematic analysis of microorganisms\u2019 metabolism for selective targeting"],"prefix":"10.1038","volume":"14","author":[{"given":"Mehdi","family":"Dehghan Manshadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payam","family":"Setoodeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habil","family":"Zare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"issue":"3","key":"65936_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000516399","volume":"77","author":"C Hill","year":"2021","unstructured":"Hill, C. Microbiome and infection: A case for \u201cselective depletion\u201d. Ann. Nutr. Metab. 77(3), 4\u20139 (2021).","journal-title":"Ann. Nutr. Metab."},{"issue":"1","key":"65936_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/med.21805","volume":"42","author":"Y Luo","year":"2022","unstructured":"Luo, Y. & Zhou, T. Connecting the dots: Targeting the microbiome in drug toxicity. Med. Res. Rev. 42(1), 83\u2013111 (2022).","journal-title":"Med. Res. Rev."},{"issue":"2","key":"65936_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/apt.14397","volume":"47","author":"C Woodhouse","year":"2018","unstructured":"Woodhouse, C., Patel, V., Singanayagam, A. & Shawcross, D. the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment. Pharmacol. Ther. 47(2), 192\u2013202 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"65936_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jhep.2018.10.019","volume":"70","author":"SK Sarin","year":"2019","unstructured":"Sarin, S. K., Pande, A. & Schnabl, B. Microbiome as a therapeutic target in alcohol-related liver disease. J. Hepatol. 70(2), 260\u2013272 (2019).","journal-title":"J. Hepatol."},{"issue":"2","key":"65936_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcmgh.2018.04.003","volume":"6","author":"CR Martin","year":"2018","unstructured":"Martin, C. R., Osadchiy, V., Kalani, A. & Mayer, E. A. The brain-gut-microbiome axis. Cell. Mol. Gastroenterol. Hepatol. 6(2), 133\u2013148 (2018).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"65936_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gtc.2016.09.007","volume":"46","author":"TG Dinan","year":"2017","unstructured":"Dinan, T. G. & Cryan, J. F. The microbiome-gut-brain axis in health and disease. Gastroenterol. Clin. 46(1), 77\u201389 (2017).","journal-title":"Gastroenterol. Clin."},{"key":"65936_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pharmthera.2015.11.012","volume":"158","author":"S Ghaisas","year":"2016","unstructured":"Ghaisas, S., Maher, J. & Kanthasamy, A. Gut microbiome in health and disease: Linking the microbiome\u2013gut\u2013brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol. Ther. 158, 52\u201362 (2016).","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"65936_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-018-1756-4","volume":"17","author":"Y-Y Chen","year":"2019","unstructured":"Chen, Y.-Y. et al. Microbiome\u2013metabolome reveals the contribution of gut\u2013kidney axis on kidney disease. J. Transl. Med. 17(1), 1\u201311 (2019).","journal-title":"J. Transl. Med."},{"key":"65936_CR9","doi-asserted-by":"crossref","unstructured":"Shankaranarayanan, D. & Raj, D. Gut microbiome and kidney disease. Clin. J. Am. Soc. Nephrol. (2022).","DOI":"10.2215\/CJN.04480422"},{"issue":"6","key":"65936_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/HCO.0000000000000445","volume":"32","author":"S Ahmadmehrabi","year":"2017","unstructured":"Ahmadmehrabi, S. & Tang, W. W. Gut microbiome and its role in cardiovascular diseases. Curr. Opin. Cardiol. 32(6), 761 (2017).","journal-title":"Curr. Opin. Cardiol."},{"issue":"1","key":"65936_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11255-021-03044-w","volume":"54","author":"Y Okuyama","year":"2022","unstructured":"Okuyama, Y. et al. The influence of gut microbiome on progression of overactive bladder symptoms: A community-based 3-year longitudinal study in Aomori, Japan. Int. Urol. Nephrol. 54(1), 9\u201316 (2022).","journal-title":"Int. Urol. Nephrol."},{"issue":"3","key":"65936_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00345-020-03243-7","volume":"39","author":"T Okamoto","year":"2021","unstructured":"Okamoto, T. et al. Altered gut microbiome associated with overactive bladder and daily urinary urgency. World J. Urol. 39(3), 847\u2013853 (2021).","journal-title":"World J. Urol."},{"issue":"1","key":"65936_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.1260","volume":"11","author":"DV Patangia","year":"2022","unstructured":"Patangia, D. V., Anthony Ryan, C., Dempsey, E., Paul Ross, R. & Stanton, C. Impact of antibiotics on the human microbiome and consequences for host health. MicrobiologyOpen. 11(1), e1260 (2022).","journal-title":"MicrobiologyOpen."},{"issue":"4","key":"65936_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095476","volume":"9","author":"S Panda","year":"2014","unstructured":"Panda, S. et al. Short-term effect of antibiotics on human gut microbiota. PloS One 9(4), e95476 (2014).","journal-title":"PloS One"},{"issue":"1","key":"65936_CR15","first-page":"17","volume":"111","author":"AA Villarreal","year":"2012","unstructured":"Villarreal, A. A., Aberger, F. J., Benrud, R. & Gundrum, J. D. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 111(1), 17\u201320 (2012).","journal-title":"WMJ"},{"issue":"1","key":"65936_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-11646-2","volume":"12","author":"Y Shimodaira","year":"2022","unstructured":"Shimodaira, Y., Watanabe, K. & Iijima, K. The risk of antibiotics and enterocolitis for the development of inflammatory bowel disease: A Japanese administrative database analysis. Sci. Rep. 12(1), 1\u20138 (2022).","journal-title":"Sci. Rep."},{"issue":"11","key":"65936_CR17","first-page":"1728","volume":"109","author":"R Ungaro","year":"2014","unstructured":"Ungaro, R. et al. Antibiotics associated with increased risk of new-onset Crohn\u2019s disease but not ulcerative colitis: A meta-analysis. ACG 109(11), 1728\u20131738 (2014).","journal-title":"ACG"},{"issue":"3","key":"65936_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s13679-021-00438-w","volume":"10","author":"N Vallianou","year":"2021","unstructured":"Vallianou, N., Dalamaga, M., Stratigou, T., Karampela, I. & Tsigalou, C. Do antibiotics cause obesity through long-term alterations in the gut microbiome? A review of current evidence. Curr. Obesity Rep. 10(3), 244\u2013262 (2021).","journal-title":"Curr. Obesity Rep."},{"issue":"4","key":"65936_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40264-016-0493-y","volume":"40","author":"C Ferrajolo","year":"2017","unstructured":"Ferrajolo, C. et al. Antibiotic-induced liver injury in paediatric outpatients: A case-control study in primary care databases. Drug Saf. 40(4), 305\u2013315 (2017).","journal-title":"Drug Saf."},{"issue":"4","key":"65936_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cld.2013.07.008","volume":"17","author":"JG Stine","year":"2013","unstructured":"Stine, J. G. & Lewis, J. H. Hepatotoxicity of antibiotics: A review and update for the clinician. Clin. Liver Dis. 17(4), 609\u2013642 (2013).","journal-title":"Clin. Liver Dis."},{"issue":"11","key":"65936_CR21","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/gutjnl-2016-312297","volume":"65","author":"G Ianiro","year":"2016","unstructured":"Ianiro, G., Tilg, H. & Gasbarrini, A. Antibiotics as deep modulators of gut microbiota: Between good and evil. Gut. 65(11), 1906\u20131915 (2016).","journal-title":"Gut."},{"issue":"1","key":"65936_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1039\/C7MD00528H","volume":"9","author":"RJ Melander","year":"2018","unstructured":"Melander, R. J., Zurawski, D. V. & Melander, C. Narrow-spectrum antibacterial agents. Medchemcomm. 9(1), 12\u201321 (2018).","journal-title":"Medchemcomm."},{"key":"65936_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fchem.2018.00359","volume":"6","author":"E Ostorhazi","year":"2018","unstructured":"Ostorhazi, E. et al. Advantage of a narrow spectrum host defense (antimicrobial) peptide over a broad spectrum analog in preclinical drug development. Front. Chem. 6, 359 (2018).","journal-title":"Front. Chem."},{"issue":"7","key":"65936_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/antibiotics9070418","volume":"9","author":"RA Alm","year":"2020","unstructured":"Alm, R. A. & Lahiri, S. D. Narrow-spectrum antibacterial agents\u2014Benefits and challenges. Antibiotics 9(7), 418 (2020).","journal-title":"Antibiotics"},{"issue":"2","key":"65936_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089082","volume":"9","author":"M Mondhe","year":"2014","unstructured":"Mondhe, M., Chessher, A., Goh, S., Good, L. & Stach, J. E. Species-selective killing of bacteria by antimicrobial peptide-PNAs. PloS One 9(2), e89082 (2014).","journal-title":"PloS One"},{"issue":"10","key":"65936_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1517\/17460441.2011.611128","volume":"6","author":"N Chandra","year":"2011","unstructured":"Chandra, N. Computational approaches for drug target identification in pathogenic diseases. Exp. Opin. Drug Discov. 6(10), 975\u2013979 (2011).","journal-title":"Exp. Opin. Drug Discov."},{"issue":"4","key":"65936_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1089\/ind.2013.0011","volume":"9","author":"MA Garcia-Albornoz","year":"2013","unstructured":"Garcia-Albornoz, M. A. & Nielsen, J. Application of genome-scale metabolic models in metabolic engineering. Ind. Biotechnol. 9(4), 203\u2013214 (2013).","journal-title":"Ind. Biotechnol."},{"key":"65936_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coisb.2017.03.001","volume":"2","author":"WJ Kim","year":"2017","unstructured":"Kim, W. J., Kim, H. U. & Lee, S. Y. Current state and applications of microbial genome-scale metabolic models. Curr. Opin. Syst. Biol. 2, 10\u201318 (2017).","journal-title":"Curr. Opin. Syst. Biol."},{"issue":"1","key":"65936_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-019-1730-3","volume":"20","author":"C Gu","year":"2019","unstructured":"Gu, C., Kim, G. B., Kim, W. J., Kim, H. U. & Lee, S. Y. Current status and applications of genome-scale metabolic models. Genome Biol. 20(1), 1\u201318 (2019).","journal-title":"Genome Biol."},{"key":"65936_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.coisb.2017.01.008","volume":"2","author":"HM Purdy","year":"2017","unstructured":"Purdy, H. M. & Reed, J. L. Evaluating the capabilities of microbial chemical production using genome-scale metabolic models. Curr. Opin. Syst. Biol. 2, 91\u201397 (2017).","journal-title":"Curr. Opin. Syst. Biol."},{"issue":"8","key":"65936_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.tibtech.2019.01.003","volume":"37","author":"KR Choi","year":"2019","unstructured":"Choi, K. R. et al. Systems metabolic engineering strategies: Integrating systems and synthetic biology with metabolic engineering. Trends Biotechnol. 37(8), 817\u2013837 (2019).","journal-title":"Trends Biotechnol."},{"issue":"2","key":"65936_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymben.2009.05.004","volume":"12","author":"TY Kim","year":"2010","unstructured":"Kim, T. Y., Kim, H. U. & Lee, S. Y. Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab. Eng. 12(2), 105\u2013111 (2010).","journal-title":"Metab. Eng."},{"issue":"20","key":"65936_CR33","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-12-1856","volume":"18","author":"L Jerby","year":"2012","unstructured":"Jerby, L. & Ruppin, E. Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin. Cancer Res. 18(20), 5572\u20135584 (2012).","journal-title":"Clin. Cancer Res."},{"key":"65936_CR34","doi-asserted-by":"crossref","unstructured":"Cesur MF, Siraj B, Uddin R, Durmu\u015f S, \u00c7ak\u0131r T. Network-based metabolism-centered screening of potential drug targets in Klebsiella pneumoniae at genome scale. Front. Cell. Infect. Microbiol. 447 (2020).","DOI":"10.3389\/fcimb.2019.00447"},{"issue":"1","key":"65936_CR35","doi-asserted-by":"publisher","first-page":"1800377","DOI":"10.1002\/biot.201800377","volume":"14","author":"OS Mohite","year":"2019","unstructured":"Mohite, O. S., Weber, T., Kim, H. U. & Lee, S. Y. Genome-scale metabolic reconstruction of actinomycetes for antibiotics production. Biotechnol. J. 14(1), 1800377 (2019).","journal-title":"Biotechnol. J."},{"issue":"11","key":"65936_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nrmicro1023","volume":"2","author":"ND Price","year":"2004","unstructured":"Price, N. D., Reed, J. L. & Palsson, B. \u00d8. Genome-scale models of microbial cells: Evaluating the consequences of constraints. Nat. Rev. Microbiol. 2(11), 886\u2013897 (2004).","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"65936_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrmicro2737","volume":"10","author":"NE Lewis","year":"2012","unstructured":"Lewis, N. E., Nagarajan, H. & Palsson, B. O. Constraining the metabolic genotype\u2013phenotype relationship using a phylogeny of in silico methods. Nat. Rev. Microbiol. 10(4), 291\u2013305 (2012).","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"65936_CR38","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cell.2015.05.019","volume":"161","author":"EJ O\u2019Brien","year":"2015","unstructured":"O\u2019Brien, E. J., Monk, J. M. & Palsson, B. O. Using genome-scale models to predict biological capabilities. Cell. 161(5), 971\u2013987 (2015).","journal-title":"Cell."},{"issue":"3","key":"65936_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nbt.1614","volume":"28","author":"JD Orth","year":"2010","unstructured":"Orth, J. D., Thiele, I. & Palsson, B. \u00d8. What is flux balance analysis?. Nat. Biotechnol. 28(3), 245\u2013248 (2010).","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"65936_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1039\/B916446D","volume":"6","author":"HU Kim","year":"2010","unstructured":"Kim, H. U., Kim, T. Y. & Lee, S. Y. Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Mol. BioSyst. 6(2), 339\u2013348 (2010).","journal-title":"Mol. BioSyst."},{"issue":"1","key":"65936_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10611861003649753","volume":"19","author":"D Perumal","year":"2011","unstructured":"Perumal, D., Samal, A., Sakharkar, K. R. & Sakharkar, M. K. Targeting multiple targets in Pseudomonas aeruginosa PAO1 using flux balance analysis of a reconstructed genome-scale metabolic network. J. Drug Target. 19(1), 1\u201313 (2011).","journal-title":"J. Drug Target."},{"issue":"5","key":"65936_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1101\/gr.2050304","volume":"14","author":"I Yeh","year":"2004","unstructured":"Yeh, I., Hanekamp, T., Tsoka, S., Karp, P. D. & Altman, R. B. Computational analysis of Plasmodium falciparum metabolism: Organizing genomic information to facilitate drug discovery. Genome Res. 14(5), 917\u2013924 (2004).","journal-title":"Genome Res."},{"issue":"6","key":"65936_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1517\/17460441.2.6.799","volume":"2","author":"T Korcsm\u00e1ros","year":"2007","unstructured":"Korcsm\u00e1ros, T., Szalay, M. S., B\u00f6de, C., Kov\u00e1cs, I. A. & Csermely, P. How to design multi-target drugs: Target search options in cellular networks. Exp. Opin. Drug Discov. 2(6), 799\u2013808 (2007).","journal-title":"Exp. Opin. Drug Discov."},{"issue":"1\u20132","key":"65936_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","volume":"12","author":"GR Zimmermann","year":"2007","unstructured":"Zimmermann, G. R., Lehar, J. & Keith, C. T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today 12(1\u20132), 34\u201342 (2007).","journal-title":"Drug Discov. Today"},{"key":"65936_CR45","doi-asserted-by":"crossref","unstructured":"Talevi, A. Multi-target pharmacology: Possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective. Front. Pharmacol. 205 (2015).","DOI":"10.3389\/fphar.2015.00205"},{"key":"65936_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-11-213","volume":"11","author":"J Schellenberger","year":"2010","unstructured":"Schellenberger, J., Park, J. O., Conrad, T. M. & Palsson, B. \u00d8. BiGG: a Biochemical Genetic and Genomic knowledgebase of large scale metabolic reconstructions. BMC Bioinf. 11, 1\u201310 (2010).","journal-title":"BMC Bioinf."},{"key":"65936_CR47","unstructured":"EPA U. Escherichia coli K\u201012 final risk assessment: Attachment I\u2014Final risk assessment of Escherichia coli K\u201012 derivatives (1997)."},{"issue":"W1","key":"65936_CR48","doi-asserted-by":"publisher","first-page":"W256","DOI":"10.1093\/nar\/gkz239","volume":"47","author":"I Letunic","year":"2019","unstructured":"Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: Recent updates and new developments. Nucl. Acids Res. 47(W1), W256\u2013W259 (2019).","journal-title":"Nucl. Acids Res."},{"issue":"7","key":"65936_CR49","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1128\/JB.01218-10","volume":"193","author":"Y-C Liao","year":"2011","unstructured":"Liao, Y.-C. et al. An experimentally validated genome-scale metabolic reconstruction of Klebsiella pneumoniae MGH 78578, i YL1228. J. Bacteriol. 193(7), 1710\u20131717 (2011).","journal-title":"J. Bacteriol."},{"key":"65936_CR50","unstructured":"Lewis, L. A., Perisin, M. A., & Tobias, A. V. Metabolic modeling of Pseudomonas putida to understand and improve the breakdown of plastic waste. CCDC Army Research Laboratory Adelphi United States (2020)."},{"issue":"10","key":"65936_CR51","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nbt.3956","volume":"35","author":"JM Monk","year":"2017","unstructured":"Monk, J. M. et al. iML1515, a knowledgebase that computes Escherichia coli traits. Nat. Biotechnol. 35(10), 904\u2013908 (2017).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"65936_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-5-8","volume":"5","author":"I Thiele","year":"2011","unstructured":"Thiele, I. et al. A community effort towards a knowledge-base and mathematical model of the human pathogen Salmonella Typhimurium LT2. BMC Syst. Biol. 5(1), 1\u20139 (2011).","journal-title":"BMC Syst. Biol."},{"issue":"50","key":"65936_CR53","doi-asserted-by":"publisher","first-page":"20338","DOI":"10.1073\/pnas.1307797110","volume":"110","author":"JM Monk","year":"2013","unstructured":"Monk, J. M. et al. Genome-scale metabolic reconstructions of multiple Escherichia coli strains highlight strain-specific adaptations to nutritional environments. Proc. Natl. Acad. Sci. 110(50), 20338\u201320343 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"65936_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-5-163","volume":"5","author":"P Charusanti","year":"2011","unstructured":"Charusanti, P. et al. An experimentally-supported genome-scale metabolic network reconstruction for Yersinia pestis CO92. BMC Syst. Biol. 5(1), 1\u201313 (2011).","journal-title":"BMC Syst. Biol."},{"issue":"4","key":"65936_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034337","volume":"7","author":"G Sigurdsson","year":"2012","unstructured":"Sigurdsson, G., Fleming, R. M., Heinken, A. & Thiele, I. A systems biology approach to drug targets in Pseudomonas aeruginosa biofilm. PLoS One. 7(4), e34337 (2012).","journal-title":"PLoS One."},{"issue":"12","key":"65936_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.tibtech.2007.09.004","volume":"25","author":"G Cottarel","year":"2007","unstructured":"Cottarel, G. & Wierzbowski, J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25(12), 547\u2013555 (2007).","journal-title":"Trends Biotechnol."},{"issue":"9","key":"65936_CR57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin","year":"2005","unstructured":"Kaelin, W. G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer. 5(9), 689\u2013698 (2005).","journal-title":"Nat. Rev. Cancer."},{"issue":"1","key":"65936_CR58","doi-asserted-by":"publisher","first-page":"fux054","DOI":"10.1093\/femsre\/fux054","volume":"42","author":"K Klobucar","year":"2018","unstructured":"Klobucar, K. & Brown, E. D. Use of genetic and chemical synthetic lethality as probes of complexity in bacterial cell systems. FEMS Microbiol. Rev. 42(1), fux054 (2018).","journal-title":"FEMS Microbiol. Rev."},{"issue":"3","key":"65936_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers, M. & Wright, G. D. Drug combinations: A strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17(3), 141\u2013155 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"65936_CR60","unstructured":"Zhang, Y. Using synthetic-lethal interactions to discover antibacterial drug targets (2022)."},{"issue":"1","key":"65936_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-18177-w","volume":"12","author":"M Dehghan Manshadi","year":"2022","unstructured":"Dehghan Manshadi, M., Setoodeh, P. & Zare, H. Rapid-SL identifies synthetic lethal sets with an arbitrary cardinality. Sci. Rep. 12(1), 1\u20139 (2022).","journal-title":"Sci. Rep."},{"issue":"6","key":"65936_CR62","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrmicro2333","volume":"8","author":"MA Kohanski","year":"2010","unstructured":"Kohanski, M. A., Dwyer, D. J. & Collins, J. J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 8(6), 423\u2013435 (2010).","journal-title":"Nat. Rev. Microbiol."},{"issue":"11","key":"65936_CR63","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.chembiol.2014.08.020","volume":"21","author":"P Murima","year":"2014","unstructured":"Murima, P., McKinney, J. D. & Pethe, K. Targeting bacterial central metabolism for drug development. Chem. Biol. 21(11), 1423\u20131432 (2014).","journal-title":"Chem. Biol."},{"key":"65936_CR64","first-page":"329","volume":"1","author":"TH Cormen","year":"2001","unstructured":"Cormen, T. H., Leiserson, C. E., Rivest, R. L. & Stein, C. Greedy algorithms. Introduction Algorithms 1, 329\u2013355 (2001).","journal-title":"Introduction Algorithms"},{"issue":"D1","key":"65936_CR65","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46(D1), D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"65936_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","volume":"53","author":"ME Falagas","year":"2019","unstructured":"Falagas, M. E., Athanasaki, F., Voulgaris, G. L., Triarides, N. A. & Vardakas, K. Z. Resistance to fosfomycin: Mechanisms, frequency and clinical consequences. Int. J. Antimicrob. Agents. 53(1), 22\u201328 (2019).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"65936_CR67","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, L., Zhou, C., Lin, Y., Liu, S., & Zeng, W., et al. Unraveling mechanisms and epidemic characteristics of nitrofurantoin resistance in uropathogenic Enterococcus faecium clinical isolates. Infect. Drug Resist. 1601\u201311 (2021).","DOI":"10.2147\/IDR.S301802"},{"key":"65936_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00239-019-09914-3","volume":"88","author":"E Christaki","year":"2020","unstructured":"Christaki, E., Marcou, M. & Tofarides, A. Antimicrobial resistance in bacteria: Mechanisms, evolution, and persistence. J. Mol. Evol. 88, 26\u201340 (2020).","journal-title":"J. Mol. Evol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65936-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T14:03:28Z","timestamp":1721138608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65936-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["65936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-65936-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.14.549016","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16446"}}